The FDA recorded a supplement on 1 October 2026 to a generic olanzapine application (ANDA 201588) held by Sandoz. Supplements to generic applications usually cover manufacturing, labelling alignment or packaging changes.
The record does not describe a new safety finding or a change in how olanzapine should be used. Indian availability is unaffected; olanzapine is widely available here as generics.
- No change to olanzapine prescribing follows from this notice
- Continue routine metabolic monitoring — weight, glucose and lipids — for patients on olanzapine
- Check the product label if a dispensed generic changes appearance or strength format
Why it matters
Reading regulatory notices for what they are avoids treating paperwork as a safety signal.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free